1. Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
- Author
-
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Theodora Tsiouda, Georgia Trakada, Anastasios Kallianos, Lemonia Veletza, Dimitris Hatzibougias, Electra Mihalopoulou, Eirini Goupou, Christoforos Kosmidis, Chrysanthi Sardeli, Haidong Huang, and Wolfgang Hohenforst-Schmidt
- Subjects
NSCLC ,Immunotherapy ,Adenocarcinoma ,Nivolumab ,Colitis ,Pneumonitis ,Pericarditis ,Diseases of the respiratory system ,RC705-779 - Abstract
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.
- Published
- 2017
- Full Text
- View/download PDF